Business Description
Usana Health Sciences Inc
NAICS : 311999
SIC : 2021
ISIN : US90328M1071
Total Employee Number:
1,570Compare
Compare
Traded in other countries / regions
USNA.USAUSJ.Germany IPO Date
2015-11-17Description
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.04 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.61 | |||||
Interest Coverage | 100.7 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.77 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.2 | |||||
3-Year EBITDA Growth Rate | -13.1 | |||||
3-Year EPS without NRI Growth Rate | -18.7 | |||||
3-Year FCF Growth Rate | -54.4 | |||||
3-Year Book Growth Rate | 8.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.71 | |||||
9-Day RSI | 53.91 | |||||
14-Day RSI | 44.71 | |||||
3-1 Month Momentum % | 24.52 | |||||
6-1 Month Momentum % | 18.4 | |||||
12-1 Month Momentum % | -27.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.66 | |||||
Quick Ratio | 1.84 | |||||
Cash Ratio | 1.6 | |||||
Days Inventory | 162.78 | |||||
Days Sales Outstanding | 2.6 | |||||
Days Payable | 29.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.6 | |||||
Shareholder Yield % | 3.32 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.45 | |||||
Operating Margin % | 4.54 | |||||
Net Margin % | -3.15 | |||||
EBITDA Margin % | 2.5 | |||||
FCF Margin % | 1.78 | |||||
OCF Margin % | 3.07 | |||||
ROE % | -5.4 | |||||
ROA % | -3.94 | |||||
3-Year ROIIC % | -25.1 | |||||
ROC (Joel Greenblatt) % | 2.82 | |||||
ROCE % | 0.48 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 7.85 | |||||
PE Ratio without NRI | 15.11 | |||||
Shiller PE Ratio | 3.46 | |||||
PS Ratio | 0.3 | |||||
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.94 | |||||
Price-to-Free-Cash-Flow | 17.46 | |||||
Price-to-Operating-Cash-Flow | 9.98 | |||||
EV-to-EBIT | 58.45 | |||||
EV-to-EBITDA | 7.56 | |||||
EV-to-Forward-EBITDA | 7.98 | |||||
EV-to-Revenue | 0.19 | |||||
EV-to-Forward-Revenue | 0.13 | |||||
EV-to-FCF | 10.81 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Projected-FCF | 0.24 | |||||
Price-to-Median-PS-Value | 0.21 | |||||
Price-to-Graham-Number | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.66 | |||||
Earnings Yield (Greenblatt) % | 1.71 | |||||
FCF Yield % | 5.76 | |||||
Forward Rate of Return (Yacktman) % | -0.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Usana Health Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 785.462 | ||
| EPS (TTM) (€) | -1.044 | ||
| Beta | 1.3283 | ||
| 3-Year Sharpe Ratio | -1.17 | ||
| 3-Year Sortino Ratio | -1.25 | ||
| Volatility % | 54.75 | ||
| 14-Day RSI | 44.71 | ||
| 14-Day ATR (€) | 0.7209 | ||
| 20-Day SMA (€) | 11.475 | ||
| 12-1 Month Momentum % | -27.99 | ||
| 52-Week Range (€) | 10.5 - 26.8 | ||
| Shares Outstanding (Mil) | 18.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Usana Health Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Usana Health Sciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 11:00 | In 166 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 | In 165 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-23 11:00 | In 48 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 | In 47 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 11:00 | 19.30 (+1.58%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 19.20 (+1.59%) | ||
| General meeting for 2026 | 2026-05-20 11:00 | 15.00 (-0.66%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 11:00 | 16.00 (+1.91%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 15.60 (-3.70%) | ||
| Sidoti Small-Cap Virtual Conference | 2026-03-18 10:45 | 14.70 (-2.00%) |
Show
Entries
Usana Health Sciences Inc Frequently Asked Questions
What is Usana Health Sciences Inc(STU:USJ)'s stock price today?
The current price of STU:USJ is €12.40. The 52 week high of STU:USJ is €26.80 and 52 week low is €10.50.
When is next earnings date of Usana Health Sciences Inc(STU:USJ)?
The next earnings date of Usana Health Sciences Inc(STU:USJ) is 2026-10-23 Est..
Does Usana Health Sciences Inc(STU:USJ) pay dividends? If so, how much?
Usana Health Sciences Inc(STU:USJ) does not pay dividend.
Press Release
Articles on Usana Health Sciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers